John Maraganore
Board Member
Beam Therapeutics Inc. (BEAM)Board Member
Kymera Therapeutics, Inc. (KYMR)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About John Maraganore
John Maraganore is recorded as Board Member at Beam Therapeutics Inc. (BEAM) and Board Member at Kymera Therapeutics, Inc. (KYMR). John Maraganore was last confirmed as CEO at Alnylam Pharmaceuticals, Inc. (ALNY) in a filing dated April 5, 2022. The proxy statement of Alnylam Pharmaceuticals, Inc. reports total compensation of $10,176,685 for John Maraganore in fiscal 2021, including a base salary of $948,500. Disclosed compensation is on record for 5 fiscal years. John Maraganore has spoken on 7 earnings calls across 1 company, most recently for Alnylam Pharmaceuticals, Inc. on October 28, 2021.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-01-01–present
-
Current
Start not stated–present
-
Start not stated–2022-04-05
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Beam Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- John Evans CEO, Chief Accounting Officer, Board Member
- Sravan Emany CFO
- Sravan K. Emany CFO
- Chirfi Guindo Board Member
- Christi Shaw Board Member
- Graham Cooper Board Member
- John Maraganore, Ph.D. Board Member
- Kathleen Walsh Board Member
- Mark Fishman Board Member
Leadership on record at Kymera Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Jeremy Chadwick, Ph.D. COO
- Brian R. Adams General Counsel
- Brian R. Adams, J.D. General Counsel
- Brian Adams Board Member
- Bruce Booth Board Member
- Bruce Jacobs Board Member
- Elena Ridloff Board Member
- Felix J. Baker, Ph.D. Board Member
- Gorjan Hrustanovic, Ph.D. Board Member
- Jared Gollob Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Alnylam Pharmaceuticals, Inc. (ALNY) | Former ChiefExecutive Officer (principal executive officer) | $948,500 | $10,176,685 |
| 2020 | Alnylam Pharmaceuticals, Inc. (ALNY) | Former ChiefExecutive Officer (principal executive officer) | $946,200 | $7,818,164 |
| 2019 | Alnylam Pharmaceuticals, Inc. (ALNY) | Former ChiefExecutive Officer (principal executive officer) | $845,000 | $7,317,856 |
| 2018 | Alnylam Pharmaceuticals, Inc. (ALNY) | Chief Executive Officer(principal executive officer) | $800,000 | $5,089,269 |
| 2017 | Alnylam Pharmaceuticals, Inc. (ALNY) | Ph.D. Chief ExecutiveOfficer (principal executive officer) | $753,548 | $1,417,394 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.